Clinical Application of Cordyceps sinensis on Immunosuppressive Therapy in Renal Transplantation

Li, Y.; Xue, Wei; Tian, Peng; Ding, Xiaoming; H, Yan; Pan, Xiaoming; Xiong, Feng

doi:10.1016/j.transproceed.2009.02.085

Cited by 31 publications

(18 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data presented in this study supported other work that demonstrated a role for C. sinensis in preventing renal transplant rejection and retarding CAN progression [30,31]. These data suggest that C. sinensis-derived formulations may provide novel treatment options for preventing graft rejection.…”

Section: Discussionsupporting

confidence: 87%

“…Previous studies have demonstrated that C. sinensis could prolong the survival of allogeneic heart grafts [29] and, in combination with CsA, had synergistic effects in blocking allogeneic graft rejection. In addition, C. sinensis in combination with reduced CsA doses decreased proteinuria and retarded chronic allograft nephropathy (CAN) progression [30,31]. Xu et al demonstrated that C. sinensis possessed certain therapeutic effects on CAN, i.e., it diminished injury to the glomerulus and tubular interstitium [32].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cordyceps sinensis Extracts Attenuate Aortic Transplant Arteriosclerosis in Rats

Zhang

Yang

Gong

et al. 2012

Journal of Surgical Research

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 87%

Section: Discussionmentioning

confidence: 99%

Cordyceps sinensis Extracts Attenuate Aortic Transplant Arteriosclerosis in Rats

Zhang

Yang

Gong

et al. 2012

Journal of Surgical Research

View full text Add to dashboard Cite

“…Study indicates that reduced dose of CsA obviously decreased the occurrence of CAN. 17 In this study, doses and levels of CsA in study group I and study group II were lower than those in control group in the first year. As a result, reduced doses of CsA may decrease occurrence of CAN, graft failure, and death, subsequently leading to improvement of 3-and 5-year patient/graft survival.…”

Section: Discussionmentioning

confidence: 45%

Long-term follow-up of co-administration of diltiazem and cyclosporine in Chinese kidney transplant recipients

et al. 2010

View full text Add to dashboard Cite

Background: Co-administration of diltiazem and cyclosporine A (CsA) in kidney transplant recipients shows improvement of renal transplantation outcomes. Methods: We respectively analyzed 1531 kidney transplant recipients treated by different immunosuppressive therapy schemes from 1986 to 2003. They were divided into three groups depending on their immunosuppressive therapy schemes: control group with a standard triple therapy without use of diltiazem; study group I with the combination of diltiazem and the standard triple therapy but slightly low CsA; study group II with combination of diltiazem and a modified standard triple therapy but lower CsA. The CsA blood concentrations, posttransplant complications, and long-term survival in the three groups were compared. Results: The results showed that the patient and allograft survival in the study group II was 69.9 and 65.1%, respectively, significantly higher than that in the control group (50.7 and 47.6%). Occurrence of hepatotoxicity and nephrotoxicity episodes was higher in the control group than those in the study group I and the study group II. The incidence of acute rejection in the control group was 30.3% (23/76), similar to 28.0% (184/657) in study group I, but statistically significantly higher than 7.6% (61/798) in the study group II. Conclusion: Combination of diltiazem and CsA in the kidney allograft recipients tends to reduce the CsA oral dosage, improve patient survival, and decrease the occurrence of hepatotoxicity and nephrotoxicity.

show abstract

“…For example, Bailing capsule, a preparation made from C. sinensis mycelia, ameliorated the rejection of renal transplant, improved renal and liver function, regulated hypoproteinemia and hyperlipidemia, stimulated hemopoietic function, and decreased the incidence of infections in patients after renal transplant (Sun et al 2004;Li et al 2009). In patients with chronic renal failure, ingestion of another cordyceps product Cs-4, called JinShuiBao, also significantly promoted renal function, which decreased serum urea and creatinine and increased total blood protein and calcium (Feng, Yang, and Li 2008).…”

Section: Protective Effect On the Kidneymentioning

confidence: 99%

Cordyceps as an Herbal Drug

Lin¹,

Li²

2011

Oxidative Stress and Disease

View full text Add to dashboard Cite

Clinical Application of Cordyceps sinensis on Immunosuppressive Therapy in Renal Transplantation

Cited by 31 publications

References 13 publications

Cordyceps sinensis Extracts Attenuate Aortic Transplant Arteriosclerosis in Rats

Cordyceps sinensis Extracts Attenuate Aortic Transplant Arteriosclerosis in Rats

Long-term follow-up of co-administration of diltiazem and cyclosporine in Chinese kidney transplant recipients

Cordyceps as an Herbal Drug

Contact Info

Product

Resources

About